References
- Harris N L, Jaffe E S, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
- Zelenetz A D, Advani R H, Byrd J C, et al. Non-Hodgkin's Lymphoma Clinical Practice Guidelines in Oncology (V.3.2008). J natl Compr Cancer Netw 2008; 6: 356–421
- Juweid M E, Stroobants S, Hoekstra O S, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571–578
- Brepoels L, Stroobants S, De Wever W, Dierickx D, Vandenberghe P, Thomas J, et al. Positron emission tomography (PET) in mantle cell lymphoma. Leuk Lymphoma 2008; 49: 1693–1701
- Cheson B D, Pfistner B, Juweid M E, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
- Kasamon Y L, Wahl R L, Ziessman H A, et al. Risk-adapted therapy of aggressive lymphoma based on FDG-PET performed after 2 or 3 cycles of initial chemotherapy. Blood 2007; 110: 1894a
- Moskowitz C, Hamlin P A, Horwitz S M, et al. Phase II Trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL. Blood 2006; 108: 532a
- Kasamon Y L, Wahl R L. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol 2008; 20: 206–219